5 results about "Maintenance therapy" patented technology

This invention belongs to the field of acute lymphoblastic leukemia (ALL) technology and discloses an ALL scoring system. The system divides the entire treatment cycle into three major phases: induction remission, consolidation therapy, and maintenance therapy. Each phase is further subdivided into sub-phases, forming a two-tiered data acquisition architecture. During data collection, baseline data such as age and fusion genes are included, along with dynamic data such as the rate of MRD decline and drug exposure concentration. Simultaneously, anchor triggering mechanisms are set at different sub-phases, making the risk score more closely aligned with the patient's real-time condition and providing a more accurate reference for clinical treatment strategy selection. The feature adaptation module matches subtype-specific biomarkers and analyzes the interaction between rare subtypes and comorbidities. The matching module calls upon a three-dimensional protocol library to select standardized protocols for common subtypes, targeted protocols for rare subtypes, and dose adjustment or drug substitution protocols for patients with comorbidities, matching more suitable protocols for different patients.

This invention belongs to the field of biomedical technology, specifically relating to the application of a pharmaceutical composition consisting of denosumab combined with an immune checkpoint inhibitor in the preparation of a drug for treating KRAS-mutant advanced non-small cell lung cancer (NSCLC). Addressing the problems of high toxicity, limited efficacy, and lack of effective prognostic biomarkers in existing maintenance therapy for KRAS-mutant advanced NSCLC, this invention experimentally demonstrates that maintenance therapy with denosumab combined with a PD-1 / PD-L1 inhibitor can significantly prolong overall survival in patients with KRAS-mutant advanced NSCLC who have not progressed after 4-6 cycles of first-line immunochemotherapy, with a lower incidence of treatment-related adverse events and better safety, especially in patients with KRAS-G12C mutations. Furthermore, this invention discovers that plasma CCER2 can serve as a prognostic biomarker. This invention provides a new, low-toxicity, high-benefit strategy for KRAS-mutant advanced NSCLC and also provides a liquid biopsy biomarker that can be used for patient stratification, possessing significant clinical application value.

This invention discloses the application of fruquintinib combined with PD-1 monoclonal antibody in maintenance therapy for HER-2 negative advanced gastric cancer / geoesophageal junction adenocarcinoma, belonging to the field of tumor treatment technology. This invention targets HER2-negative advanced gastric cancer or gastroesophageal junction adenocarcinoma, specifically patients who achieve disease control after 3 months of first-line induction therapy with PD-1 monoclonal antibody combined with oxaliplatin, followed by maintenance therapy with fruquintinib combined with PD-1 monoclonal antibody without chemotherapy. The maintenance therapy regimen provided by this invention improves patients' quality of life and prolongs overall survival while delaying disease progression, and has significant clinical implications.

Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and / or maintenance therapy.